Quipt Home Medical Corp’s recent filing unveils that its Exec VP Operations Gamble Patrick Dennis acquired Company’s shares for reported $41634.0 on Dec 26 ’24. In the deal valued at $2.45 per share,17,000 shares were bought. As a result of this transaction, Gamble Patrick Dennis now holds 40,057 shares worth roughly $86523.12000000001.
Canaccord Genuity downgraded its Quipt Home Medical Corp [QIPT] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who decreased its forecast for the stock in mid May from “a Mkt perform” to “an Underperform”. Raymond James also remained covering QIPT and has decreased its forecast on February 16, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of QIPT
On Monday, Quipt Home Medical Corp [NASDAQ:QIPT] saw its stock jump 8.00% to $2.16. Over the last five days, the stock has gained 24.86%. Quipt Home Medical Corp shares have fallen nearly -29.18% since the year began. Nevertheless, the stocks have fallen -34.74% over the past one year. While a 52-week high of $4.07 was reached on 01/31/25, a 52-week low of $1.35 was recorded on 05/16/25. SMA at 50 days reached $2.00, while 200 days put it at $2.55.
Levels Of Support And Resistance For QIPT Stock
The 24-hour chart illustrates a support level at 2.05, which if violated will result in even more drops to 1.95. On the upside, there is a resistance level at 2.24. A further resistance level may holdings at 2.32. The Relative Strength Index (RSI) on the 14-day chart is 58.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 11.11%. Stochastics %K at 76.56% indicates the stock is a holding.
The most recent change occurred on October 20, 2021 when The Benchmark Company began covering the stock and recommended ‘”a Buy”‘ rating along with a $7.50 price target.
